WuXi Biologics details capacity expansion for complex biologics

WuXi Biologics hosted its third annual Basel CRDMO+ Day on October 19, 2026, where industry professionals discussed the challenges of developing and manufacturing increasingly complex biologics. The company announced plans to expand its annual capacity for approximately 300 IND programs and 20 BLA programs by 2027, supported by 1,064 integrated projects.

The event highlighted the industry shift toward advanced modalities such as bispecific antibodies and ADCs, which require specialized manufacturing and execution. WuXi Biologics' capacity expansion addresses the growing demand for supporting innovation at scale in the biopharmaceutical sector.